Evangelos Giamarellos-Bourboulis: Highlights from ECCMID 2022
Key clinical highlights and key takeaways from ECCMID 2022 are discussed in this interview with touchINFECTIOUS DISEASES Editorial Board member, Dr Evangelos Giamarellos-Bourboulis (Attikon University Hospital, Chaidari, Greece; Chair, European Sepsis Alliance). He discusses the burden of drug resistance in antimicrobials, and the main drugs in the market and emerging treatments. He also discusses his thoughts on the latest advances in his research group.
- What are the key clinical highlights from ECCMID 2022? (0:16)
- What are the hot topics and latest research you are looking forward to exploring in 2022? (3:07)
Disclosures: Evangelos Giamarellos-Bourboulis receives honoraria (paid to the University of Athens) from Abbott CH, Brahms, ThermoFisher GmbH Germany, GSK, and Sobi; he is also a consultant for Abbott CH, Fab’nTech, InflaRx GmbH, UCB, Sobi, and Xbiotech Inc; he also receives research grants (paid to the University of Athens) from AbbVie USA, InflaRx GmbH, Novartis, and UCB; he also receives research grants (paid to the Hellenic Institute for the Study of Sepsis) from Abbott CH, bioMérieux France, Johnson & Johnson, MSD, Sobi, and ThermoFisher Brahms GmbH. Evangelos Giamarellos-Bourboulis also received EU research funding from Horizon 2020 ITN European Sepsis Academy (granted to the University of Athens), Horizon 2020 ImmunoSep and RISCin COVID (granted to the Hellenic Institute for the Study of Sepsis), and Horizon 2020 EPIC-CROWN-2 (granted to the Hellenic Institute for the Study of Sepsis).
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of ECCMID 2022
Share this Video
Related Videos In COVID-19
Molnupiravir, an oral antiviral against SARS-CoV-2: Chris Butler, ECCMID 2023
Molnupiravir, an oral antiviral against SARS-CoV-2 was first granted emergency use authorisation in 2021 to reduce the risk of hospitalisation and death in mild to moderate COVID-19 with increased risk of developing severe disease. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the mechanism of action of […]
PANORAMIC trial – Molnupiravir efficacy in adults with COVID-19 at increased risk of adverse outcomes: Chris Butler, ECCMID 2023
PANORAMIC (ISRCTN30448031) was a multicentre, open-label, randomized controlled trial investigating novel treatments for COVID-19 in the UK. We were delighted to speak with Prof. Chris Butler (University of Oxford, Oxford, UK) to discuss the PANORAMIC study results, and how these insights will optimise the use of molnupiravir in clinical practice. Catch up: Interview with Prof. […]
COVID-19 vaccine development, updates and advances: Christoph Spinner, ECCMID 2023
The COVID-19 pandemic brought about the accelerated development of vaccinations to protect against variants of SARS-CoV-2, recently new targets of broad protection against potential future variants have been outlined and numerous vaccine candidates are in pre-clinical and clinical development. It was a pleasure to speak with Editorial Board member Dr. Christoph Spinner (Technical University of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!